Key Details
Price
$30.00Annual ROE
31.67%Beta
0.58Events Calendar
Next earnings date:
Feb 14, 2025Recent quarterly earnings:
Oct 24, 2024Recent annual earnings:
Feb 15, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
May 15, 2000Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
DUBLIN, Nov. 25, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) has announced that its management will take part in two investor conferences soon. The 7th Annual Evercore ISI HealthCONx Conference is scheduled for Tuesday, Dec. 3, 2024, at 10:25 a.m.
Alkermes has moved from earning money through royalties to selling its own products, thanks to the success of Lybalvi, Vivitrol, and Aristada. The company’s ALKS 2680, which is in Phase 2 trials for treating narcolepsy and hypersomnia, could be a game-changer in a market expected to reach $7.3 billion by 2032. With $908.9 million in available funds and a positive cash flow of $73.3 million in the third quarter, Alkermes is well-positioned to support its research and development as well as its operations.
ALKS has announced that its results for the third quarter of 2024 were not as strong as anticipated. However, the net sales of its own products have risen compared to the previous year.
Alkermes plc (NASDAQ:ALKS) will hold its Q3 2024 Earnings Conference Call on October 24, 2024, at 8:00 AM ET. The call will feature company representatives including Sandra Coombs, Richard Pops, Todd Nichols, and Blair Jackson. Various analysts from firms like TD Cowen, Evercore, and JPMorgan will also participate in the call.
Alkermes (ALKS) reported quarterly earnings of $0.73 per share, which is lower than the Zacks Consensus Estimate of $0.78 per share. This is an increase from the earnings of $0.64 per share from the same period last year.
The main figures for Alkermes (ALKS) provide an overview of the company's performance for the quarter that ended in September 2024. However, it could be useful to look at some of its important metrics in relation to Wall Street predictions and the results from the same period last year.
In addition to Wall Street's predictions for Alkermes' (ALKS) earnings, take a look at forecasts for some important metrics to better understand how the company performed in the quarter that ended in September 2024.
Are you looking for ways to choose powerful stocks that can outperform the market for your investment portfolio? The Zacks Style Scores can help you with that.
DUBLIN, Sept. 25, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) has announced that it will hold an investor event for financial analysts and institutional investors on Wednesday, October 9, 2024, beginning at 10:00 a.m.
Alkermes plc has announced that it will present clinical data from its phase 1b study of ALKS 2680 for narcolepsy type 2 and idiopathic hypersomnia at the European Sleep Research Society's 27th Congress, Sleep Europe 2024. The data from the narcolepsy type 2 cohort will be shared in an oral presentation, while the data from the idiopathic hypersomnia cohort will be featured in a poster presentation. The event is scheduled for September 2024 in Dublin.
FAQ
- What is the primary business of Alkermes?
- What is the ticker symbol for Alkermes?
- Does Alkermes pay dividends?
- What sector is Alkermes in?
- What industry is Alkermes in?
- What country is Alkermes based in?
- When did Alkermes go public?
- Is Alkermes in the S&P 500?
- Is Alkermes in the NASDAQ 100?
- Is Alkermes in the Dow Jones?
- When was Alkermes's last earnings report?
- When does Alkermes report earnings?
- Should I buy Alkermes stock now?